PD-1 Inhibition Shows 'Clear' Benefit in Nasopharyngeal Carcinoma

(MedPage Today) -- Adding the PD-1 inhibitor tislelizumab to chemotherapy led to a progression-free survival (PFS) improvement for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to updated results from a phase III...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news